Plaque Psoriasis and Psoriatic Arthritis Patient and Prescriber Audiences
Plaque Psoriasis & Psoriatic Arthritis
In our Audience Quality Test, the plaque psoriasis & PsA audience held 2.30× more high-fit households than the U.S. population, and 1.61× more qualified households. Brands can reach patients and the prescribers who treat them, with results reported every week. At $1.50 to $3.00 CPM, these audiences are priced at approximately 50% or less of the market rate.
Qualified audience
Every household and prescriber is scored 0 to 100 for fit to this condition. You buy only the tiers that qualify.
$1.50 to $3.00 CPM
Priced at approximately 50% or less of the market rate for pharma audiences.
Weekly measurement
Qualified reach, lift against the national baseline, and reach by state, reported every week.
Patients · DTC validated
- Households in test audience
- 1.4M
- High-fit people, national (score 73+)
- 15.4M
- Qualified people, national (score 67+)
- 48.1M
- Digitally active, qualified
- 10.1M
Share of households clearing the high-fit bar (score 73+). Qualified tier (score 67+): 30.8% in the test audience vs 19.1% nationally.
Prescribers · HCP active Type 1 NPIs
| Specialty | NPIs | At home |
|---|---|---|
| Treating | 27,301 | 17,591 |
| Dermatology | 18,583 | 12,142 |
| Rheumatology | 8,718 | 5,449 |
| Referring | 705,983 | 426,518 |
| Family & internal medicine | 327,135 | 200,836 |
| Primary care nurse practitioners | 378,848 | 225,682 |
| Total prescribers | 733,284 | 444,109 |
Counted by primary NUCC taxonomy in the CMS NPPES registry (September 2026). "At home" means matched to a home address in Semcasting's NPI file, for reach on CTV, streaming and display. Referring counts exclude doctors already counted as treating.
Where qualified patients concentrate top states by share
- Massachusetts
- Connecticut
- New Jersey
- New Hampshire
- District of Columbia
- Colorado
Common questions
How many prescribers treat plaque psoriasis & PsA?
27,301 active Type 1 NPIs in the treating specialties (dermatology and rheumatology), 17,591 of them matched to a home address for CTV, streaming and display. Another 705,983 referring prescribers are counted separately. Counts come from the CMS NPPES registry, September 2026.
How was the plaque psoriasis & PsA patient audience validated?
In Semcasting's Audience Quality Test, the plaque psoriasis & PsA audience held 2.30x more high-fit households than the U.S. population (score 73 or higher) and 1.61x more qualified households (score 67 or higher). During a campaign the same comparison runs every week on the households actually reached.
Does the plaque psoriasis & PsA audience use diagnosis, claims or prescription data?
No. Patient audiences are built from peer-reviewed, population-level public health reporting and population surveys, scored against Semcasting's national adult file. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.
Evidence base primary sources for plaque psoriasis & PsA
- Disease associationNational Psoriasis Foundation prevalence reporting
- Peer-reviewed studyArmstrong et al. 2021, JAMA Dermatology (NHANES)
- Population surveyCDC NHANES
How the audience is built
Patient counts for plaque psoriasis & PsA come from physician-reported registries, diagnostic population surveys, and federal (CDC, CMS, NIH) and disease-association reporting, listed above. Each of 251.7M U.S. adult records is scored 0 to 100 for fit to those published patient profiles by age, gender and income. No published geographic breakdown meets our standard for this condition, so it is scored on demographic fit alone. Qualified means a score of 67 or higher. High-fit means 73 or higher.
How quality is confirmed
Audience quality has historically been confirmed through holdout sampling: a delivered audience is compared with the full national panel at the same fixed score cutoffs, and the difference is reported as lift. During a campaign, the same comparison runs every week on the households actually reached.
What it is not
Qualified audiences are not built from modeled claims data extrapolated from a few locations. They come from peer-reviewed, population-level public health reporting on patient profiles and population surveys. No diagnosis records, claims, prescriptions or PHI are used, and the score says nothing about any one person's health.